BioVie Inc (BIVI) Stock Analysis
Verdict: AVOID
Severe cash burn ($19M/yr) and Phase 2 trial miss force equity dilution — insider buys fail to offset primary endpoint failure risks.
Investment score: 34/100
Analysis as of
Is BioVie Inc stock worth reviewing? AI model thesis
BioVie Inc. is a micro-cap pre-revenue clinical biotech facing severe cash burn, dilution risk, and mixed Phase 2 trial outcomes.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 70/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
BioVie Inc opportunities and risks
What speaks for BIVI
- Subgroup efficacy in Phase 2 Long COVID trial
What speaks against BIVI
- Clinical failure of lead candidate bezisterim in broad patient populations
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BIVI | n/a | 0.0x | n/a | 0.0% | 0.0% | -137.1% |
| PASG | n/a | 0.0x | 0.3x | 0.0% | 0.0% | -212.8% |
| CNSY | n/a | 3.4x | n/a | 89.6% | -620.7% | -163.0% |
| INTI | n/a | 0.0x | n/a | 0.0% | 0.0% | -21.0% |
| MBRX | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -612.0% |
| SYBX | n/a | 0.0x | n/a | 0.0% | 0.0% | -28.3% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -163.0% |
Frequently asked questions about BioVie Inc (BIVI)
Is BIVI stock a good investment?
The cached TradeMates AI model rates BioVie Inc as AVOID with an investment score of 34/100. BioVie Inc. is a micro-cap pre-revenue clinical biotech facing severe cash burn, dilution risk, and mixed Phase 2 trial outcomes. This is algorithmic model output, not personal investment advice.
Is BIVI stock a buy?
The TradeMates model verdict for BIVI is AVOID with an investment score of 34/100. Treat this as a model signal to review, not a personal buy recommendation.